Warfarin pharmacogenetics

被引:100
作者
Limdi, Nita A. [1 ]
Veenstra, David L. [2 ,3 ]
机构
[1] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA
[2] Univ Washington, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA
[3] Univ Washington, Inst Publ Hlth Genet, Seattle, WA 98195 USA
来源
PHARMACOTHERAPY | 2008年 / 28卷 / 09期
关键词
warfarin; pharmacogenctics; cytochrome P4502C9; CYP2C9; vitarrim K epoxide reductase; VKORC1;
D O I
10.1592/phco.28.9.1084
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Significant interest in the pharmacogenetics of warfarin therapy has been triggered with the recent package insert update that highlights the potential role of pharmacogenetics in improving the safety and effectiveness of warfarin. We review the evidence of the influence of the two key genes of interest, the cytochrome P450 2C9 gene, CYP2C9, and the vitamin K epoxide reductase complex 1 gene, VKORC1, on warfarin response and discuss the implications of current knowledge for clinical practice. The influence of CYP2C9 and VKORC1 genotypes on warfarin dose requirements has been consistently demonstrated in diverse racial and ethnic patient groups in observational studies and randomized clinical trials. Dosing algorithms have been developed that incorporate clinical, demographic, and genetic information to help select a warfarin starting dose. Furthermore, CYP2C9 variant genotypes have been associated with a significantly increased risk of serious bleeding events. However, evidence to date from prospective, controlled studies has not demonstrated an added benefit of incorporating genotype-guided therapy in improving anticoagulation control or in preventing or reducing the risk of hemorrhagic or thromboembolic complications. Research efforts designed to evaluate the effectiveness of genotype-guided therapy in improving outcomes are under way However, the routine use of CYP2C9 and VKORC1 genotyping in the general patient population who begin warfarin therapy is not supported by evidence currently available.
引用
收藏
页码:1084 / 1097
页数:14
相关论文
共 94 条
  • [11] Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians
    Borgiani, Paold
    Ciccacci, Cinzia
    Forte, Vittorio
    Romano, Silvia
    Federici, Giorgio
    Novelli, Giuseppe
    [J]. PHARMACOGENOMICS, 2007, 8 (11) : 1545 - 1550
  • [12] CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation:: A prospective randomized controlled study
    Caraco, Y.
    Blotnick, S.
    Muszkat, M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (03) : 460 - 470
  • [13] Chamberlain M A, 2001, J Am Board Fam Pract, V14, P16
  • [14] Comparison of an anticoagulation clinic with usual medical care -: Anticoagulation control, patient outcomes, and health care costs
    Chiquette, E
    Amato, MG
    Bussey, HI
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (15) : 1641 - 1647
  • [15] A new vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with decreased stability of CYP2C9 enzyme
    D'Ambrosio, R. L.
    D'Andrea, G.
    Cafolla, A.
    Faillace, F.
    Margaglione, M.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (01) : 191 - 193
  • [16] A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin
    D'Andrea, G
    D'Ambrosio, RL
    Di Perna, P
    Chetta, M
    Santacroce, R
    Brancaccio, V
    Grandone, E
    Margaglione, M
    [J]. BLOOD, 2005, 105 (02) : 645 - 649
  • [17] Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans
    Dickmann, LJ
    Rettie, AE
    Kneller, MB
    Kim, RB
    Wood, AJJ
    Stein, CM
    Wilkinson, GR
    Schwarz, UI
    [J]. MOLECULAR PHARMACOLOGY, 2001, 60 (02) : 382 - 387
  • [18] RISK-FACTORS FOR COMPLICATIONS OF CHRONIC ANTICOAGULATION - A MULTICENTER STUDY
    FIHN, SD
    MCDONELL, M
    MARTIN, D
    HENIKOFF, J
    VERMES, D
    KENT, D
    WHITE, RH
    [J]. ANNALS OF INTERNAL MEDICINE, 1993, 118 (07) : 511 - 520
  • [19] Underutilization of antithrombotic therapy in elderly rural patients with atrial fibrillation
    Flaker, GC
    McGowan, DJ
    Boechler, M
    Fortune, G
    Gage, B
    [J]. AMERICAN HEART JOURNAL, 1999, 137 (02) : 307 - 312
  • [20] Pharmacology and pharmacogenetics of warfarin and other coumarins when used with supplements
    Gage, BF
    Milligan, PE
    [J]. THROMBOSIS RESEARCH, 2005, 117 (1-2) : 55 - 59